丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06872 丹诺医药-B

未开盘 09-22 16:08:11

130.900

+3.200

+2.51%

最高135.700	最低117.300	成交量52.17万
今开128.600	昨收127.700	日振幅14.41%
总市值68.50亿	流通市值68.50亿	总股本5,233万
成交额6,806万	换手率1.00%	流通股本5,233万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06872","market":"HK","secType":"STK","nameCN":"丹诺医药-B","latestPrice":130.9,"timestamp":1790064491385,"preClose":127.7,"halted":0,"volume":521650,"delay":0,"changeRate":0.02505873140172281,"floatShares":52328926,"shares":52328926,"eps":-3.845134,"marketStatus":"未开盘","change":3.2,"latestTime":"09-22 16:08:11","open":128.6,"high":135.7,"low":117.3,"amount":68064235,"amplitude":0.144088,"askPrice":131,"askSize":950,"bidPrice":130.8,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-3.065,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790127000000},"marketStatusCode":0,"adr":0,"listingDate":1779379200000,"exchange":"SEHK","adjPreClose":127.7,"openAndCloseTimeList":[[1790040600000,1790049600000],[1790053200000,1790064000000]],"volumeRatio":2.624918,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06872","defaultTab":"news","newsList":[{"id":"2669114700","title":"港股异动 | 丹诺医药-B(06872.HK)盘中涨超6% TNP-2092 2a期概念验证临床试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114700","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669114700?lang=zh_cn&edition=full","pubTime":"2026-09-22 15:49","pubTimestamp":1790063396,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06872","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187398373","title":"丹诺医药-B（06872）拟设立2026年H股股份奖励计划并修订公司章程","url":"https://stock-news.laohu8.com/highlight/detail?id=1187398373","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187398373?lang=zh_cn&edition=full","pubTime":"2026-09-21 22:06","pubTimestamp":1789999601,"startTime":"0","endTime":"0","summary":"丹诺医药（苏州）股份有限公司9月21日公告称，公司董事会已决议：制订2026年H股股份奖励计划；修订《丹诺医药（苏州）股份有限公司章程》。上述事项尚需提交公司即将召开的临时股东会审议批准后方可生效。公司表示，将在适当时候刊发载有上述议案详情及临时股东会通知的通函。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669691951","title":"丹诺医药-B(06872.HK)：制订2026年H股股份奖励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2669691951","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669691951?lang=zh_cn&edition=full","pubTime":"2026-09-21 22:01","pubTimestamp":1789999265,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06872","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666335517","title":"华福证券：PJI无手术时代临近 创新疗法需求迫切","url":"https://stock-news.laohu8.com/highlight/detail?id=2666335517","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666335517?lang=zh_cn&edition=full","pubTime":"2026-09-11 09:37","pubTimestamp":1789090634,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华福证券发布研报称，全球人工关节感染疾病负担沉重且持续扩容，当前标准手术治疗方案2年累计再感染率仍超10%，临床对突破生物膜屏障的创新疗法需求迫切。当前抗菌肽，噬菌体，单抗均定位于手术清创后联合使用减少再感染风险，进一步避免二次手术。而关节腔注射给药的关节滑液浓度会更高，2a数据显示，在小样本早期/急性PJI中，无手术情况下，利福喹酮12个月中的治疗成功率为100%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872","BK1161","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120373262","title":"丹诺医药-B公布Rifaquizinone（TNP-2092）IIa期概念验证积极数据，为假体周围关节感染首款非手术候选疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1120373262","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120373262?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:32","pubTimestamp":1789039961,"startTime":"0","endTime":"0","summary":"丹诺医药-B今日宣布，其核心在研药物Rifaquizinone在IIa期概念验证研究中取得积极结果。这一候选药物被视为针对假体周围关节感染的首个非手术疗法候选方案。在临床研究中，Rifaquizinone展现出令人鼓舞的安全性与疗效信号。丹诺医药进一步指出，IIa期研究的积极结果不仅验证了药物的早期临床潜力，也为其快速推进至后期开发阶段提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665340203","title":"港股异动 | 丹诺医药-B(06872)涨超7% 日前获纳入港股通名单 利福喹酮IIa期概念验证数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2665340203","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665340203?lang=zh_cn&edition=full","pubTime":"2026-09-08 15:04","pubTimestamp":1788851053,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，丹诺医药-B涨超7%，该股昨日曾冲高涨超15%，随后跳水收跌逾8%。截至发稿，涨7.45%，报165.8港元，成交额2741.28万港元。消息面上，9月7日起，丹诺医药正式获纳入港股通名单。公司表示，此次获纳入港股通，是资本市场对本公司投资价值、市值规模及流动性的全面认可。丹诺医药专注于细菌感染及细菌代谢相关疾病领域。9月7日，丹诺医药公布，利福喹酮治疗人工关节感染的IIa期概念验证临床取得积极结果，多中心IIb期试验已启动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872","VXUS","FLHK","KCAI","BK1161","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665239878","title":"丹诺医药：利福喹酮IIa期概念验证数据积极 IIb期临床获批启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2665239878","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665239878?lang=zh_cn&edition=full","pubTime":"2026-09-07 08:59","pubTimestamp":1788742740,"startTime":"0","endTime":"0","summary":"9月7日，丹诺医药（06872）发布公告，公司在研全球首创三靶点新药利福喹酮(TNP-2092)，关节腔内注射用于治疗人工关节感染（PJI）的IIa期概念验证临床试验获得积极顶线结果。依托该概念验证数据，多中心IIb期临床试验已获国家药监局许可，近期正式启动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866214337.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866214337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665600243","title":"丹诺医药-B(06872.HK)：利福喹酮(TNP-2092)治疗人工关节感染IIa期概念验证临床试验取得积极结果及多中心IIb期临床试验启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2665600243","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665600243?lang=zh_cn&edition=full","pubTime":"2026-09-07 08:26","pubTimestamp":1788740800,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06872","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164901141","title":"丹诺医药-B（06872）：利福喹酮TNP-2092治疗人工关节感染IIa期试验获积极结果，多中心IIb期临床启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1164901141","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164901141?lang=zh_cn&edition=full","pubTime":"2026-09-07 08:05","pubTimestamp":1788739529,"startTime":"0","endTime":"0","summary":"2026年9月7日，丹诺医药-B公告称，其在研新药候选物利福喹酮用于人工关节感染关节腔内注射治疗的IIa期概念验证临床试验取得积极顶线结果，并已获国家药品监督管理局批准启动多中心IIb期临床试验。IIa期试验在中国开展，共入组10例患者。丹诺医药-B目前拥有包含八个创新项目的管线，其中核心产品包括：用于治疗幽门螺杆菌感染等适应症的利福特尼唑及本次取得积极进展的利福喹酮。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144847565","title":"丹诺医药-B8月股份维持稳定，未有新增发行或回购","url":"https://stock-news.laohu8.com/highlight/detail?id=1144847565","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144847565?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:56","pubTimestamp":1788339362,"startTime":"0","endTime":"0","summary":"丹诺医药（苏州）股份有限公司于2026年9月2日发布了截至2026年8月31日的证券变动月报表。公告显示，本期公司已发行股本维持稳定，无新增发行、购回或库藏股变动。报告期内，丹诺医药-B普通股H股的期初和期末数量均为52,328,926股，每股面值人民币1元，对应已发行股本合计人民币52,328,926元。公司表示，截至8月31日，已满足适用的香港联交所公眾持股量要求。报告显示，丹诺医药-B的股本数量在报告期内未发生变动，股本结构总体保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662079166","title":"丹诺医药-B(06872.HK)发布中期业绩，股东应占亏损6424.5万元 同比收窄17.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662079166","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662079166?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:15","pubTimestamp":1787735733,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06872","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189688927","title":"丹诺医药-B2026年上半年业绩：营收0元","url":"https://stock-news.laohu8.com/highlight/detail?id=1189688927","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189688927?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:06","pubTimestamp":1787735219,"startTime":"0","endTime":"0","summary":"公司2026年上半年尚无商业化产品，营业收入为0元。研发开支为3,132.10万元，同比增长约19%，主要由于加快推进核心候选药物NDA审评及其他管线产品的临床进展所致。行政开支为3,201.30万元，同比增长约72%，部分原因在于上市开支及限制性股票成本增加。经营活动现金流出净额约为5,922.70万元，同比增长约48%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"丹诺医药-B2026年上半年业绩：营收0元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661135262","title":"丹诺医药-B(06872.HK)获纳入恒生综合指数 有望成为港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2661135262","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661135262?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:45","pubTimestamp":1787309129,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06872","BK1161","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660023238","title":"【生物医药小白投研】第一篇：打破认知盲区，建立底层框架","url":"https://stock-news.laohu8.com/highlight/detail?id=2660023238","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660023238?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:30","pubTimestamp":1787214600,"startTime":"0","endTime":"0","summary":"生物医药是A股和港股中最特殊的赛道，没有之一。本篇旨在帮助读者打破固有思维，搭建生物医药投资的底层认知框架，为后续的选择、排雷、交易体系打好基础。康方生物：2025年商业化产品销售收入30.33亿元，同比增长51.48%。目前该公司已有4款产品获批上市。典型案例是2026年ASCO期间，康方生物和信达生物等发布了重磅临床数据，但当日股价表现平平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650513943&idx=1&sn=7cbba7ab46d98a94d953d8e9b60809e2&chksm=f30e7cf71bc535c0c64240524852e4b36187629cca446e9bd382f04ea70a74b68d1ffd38d5ce&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU0348735423.USD","LU2039709279.SGD","BK1583","LU0540923850.HKD","IE0008368742.USD","LU2097828474.EUR","09939","LU1152091168.USD","LU0067412154.USD","LU1951186391.HKD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU1328277881.USD","LU1720050803.USD","LU2097828805.USD","06990","IE00B5MMRT66.SGD","LU0244354667.USD","LU0348783233.USD","LU1226287529.USD","LU2097828714.EUR","LU0326950275.SGD","LU2778985437.USD","01093","LU0348767384.USD","LU0561508036.HKD","KURE","06872","IE00BPRC5H50.USD","01801","LU0463099449.HKD","BK1521","LU2097828557.USD","LU0634319403.HKD","LU2097828631.EUR","IE00BZ08YS42.EUR","LU2488822045.USD","LU0140636845.USD","03692","LU1226287875.USD","LU2328871848.SGD","LU2242644610.SGD","01177","02396","09926","LU0501845795.SGD","LU1226287792.SGD","IE0008369823.USD","SG9999004220.SGD","LU0880133367.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195766769","title":"丹诺医药-B（06872）拟于8月26日审议2026年中期业绩及股息事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1195766769","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195766769?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:36","pubTimestamp":1786696593,"startTime":"0","endTime":"0","summary":"丹诺医药-B（06872）14日公告称，公司董事会将于2026年8月26日（星期三）召开会议，主要议程包括：一是审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布；二是考虑派发中期股息（如有）。\\n\\n公告显示，董事会目前由执行董事马振坤博士（兼董事会主席、首席执行官及总经理）、非执行董事宋高广博士，以及独立非执行董事李维刚先生、倪琳博士和李乐平博士组成。\\n\\n公司提醒投资者，相关中期业绩及分红方案的最终结果仍待董事会正式审议并通过后另行公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130610641","title":"丹诺医药-B 7月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1130610641","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130610641?lang=zh_cn&edition=full","pubTime":"2026-08-03 14:55","pubTimestamp":1785740137,"startTime":"0","endTime":"0","summary":"丹诺医药-B于2026年8月3日发布2026年7月股份变动月报表，报告期为2026年7月1日至7月31日。根据公告，截至报告期末，公司普通股H股已发行股份数为52,328,926股，与上个月末保持一致。公告显示，报告期内公司已发行及注册股本无新增或减少情况，普通股H股的已发行股份由上月底的52,328,926股保持不变，库藏股数量亦为0股。公司未发生任何股份购回、注销及新发行情况，也未披露股份期权或股权激励计划相关变动事宜。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193535160","title":"丹诺医药-B 2026年6月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1193535160","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193535160?lang=zh_cn&edition=full","pubTime":"2026-07-03 14:04","pubTimestamp":1783058666,"startTime":"0","endTime":"0","summary":"丹诺医药(苏州)股份有限公司于2026年7月3日发布2026年6月股份变动月报表。公告显示，截至2026年6月30日，公司已发行普通股（H股）数量为52,328,926股，与5月底数量一致，报告期内无新增发行、购回、注销或股份回购后持作库藏的情况。公司确认，截至本月末，已满足香港联合交易所有限公司的公众持股量要求。报告期内，公司无可换股债券、股权激励及其他权益工具的变动事宜。截至6月底，公司股本结构整体保持稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00100","01511","09630","03887","06656","07666","01133","06658","BK4585","02335","03310","06872","01651","02670","00600","00412","03625","07630","02672","01191","06938","00376","07688","01392","01081","01779","02632","03388","09637","02526","03277","06675","00340","01609","02729","01879","02553","01286","00863","02272","BK4588","01866","02142","02723","02616","06636","01021","01672","01236","00068","01956","02696","03661","02726","01440","06106","03355"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2641870064","title":"丹诺医药-B(06872)：宋高广获委任为薪酬与考核委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2641870064","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641870064?lang=zh_cn&edition=full","pubTime":"2026-06-08 22:12","pubTimestamp":1780927959,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丹诺医药-B(06872)发布公告，非执行董事宋高广博士已获委任为董事会薪酬与考核委员会成员，任期自2026年6月8日起生效，至第一届董事会任期届满之日止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641813110","title":"丹诺医药-B(06872)：Michael James Bakes辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2641813110","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641813110?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:48","pubTimestamp":1780660131,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丹诺医药-B(06872)发布公告，由于个人工作原因调整，Michael James Bakes先生已辞任非执行董事并因此自动辞去董事会薪酬与考核委员会成员职务，自2026年6月5日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tennortherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0642},{"period":"1month","weight":-0.3392},{"period":"3month","weight":-0.5034},{"period":"6month","weight":0.7292},{"period":"ytd","weight":0.7292}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":-0.0354},{"period":"3month","weight":0.0716},{"period":"6month","weight":0.0093},{"period":"1year","weight":-0.0477},{"period":"ytd","weight":-0.0212}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"丹诺医药（苏州）股份有限公司是一家主要从事发现、开发创新药产品的中国公司。该公司专注于细菌感染和代谢相关疾病领域。该公司的产品包括治疗幽门螺杆菌的新分子实体候选药物利福特尼唑(TNP-2198)、三靶点抗菌候选药物利福喹酮(TNP-2092)注射剂和治疗肠道菌群代谢相关疾病的多靶点抗菌候选药物TNP-2092口服制剂等。","exchange":"SEHK","name":"丹诺医药-B","nameEN":"TENNOR THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丹诺医药-B(06872)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丹诺医药-B,06872,丹诺医药-B股票,丹诺医药-B股票老虎,丹诺医药-B股票老虎国际,丹诺医药-B行情,丹诺医药-B股票行情,丹诺医药-B股价,丹诺医药-B股市,丹诺医药-B股票价格,丹诺医药-B股票交易,丹诺医药-B股票购买,丹诺医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丹诺医药-B(06872)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}